| Literature DB >> 23938771 |
Abstract
The Session 9 of the Modern Vaccine Adjuvant/Formulation meeting pointed out the permanent need for vaccine improvement and for adjuvant development. Indeed, the increasing use of recombinant subunit vaccines for both parenteral and mucosal vaccination necessitates the development of improved adjuvants. This session dealt with strategies for the development of new vaccine adjuvants with respect to the availability of new molecules targeting specifically the receptors of the systemic or mucosal immune system.Keywords: T-cell response; adjuvants; formulation; mucosal immunity
Mesh:
Substances:
Year: 2013 PMID: 23938771 PMCID: PMC3906371 DOI: 10.4161/hv.26074
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN: 2164-5515 Impact factor: 3.452